U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Patients with R/R KMT2A- Rearranged (MLLr) Acute Leukemia December 12, 2022
FDA Approves REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with R/R AML with a Susceptible IDH1 Mutation December 5, 2022
Ph 3 trial of SYK inhibitor, entospletinib, for the treatment of newly diagnosed patients with NPM1-mutated AML to be discontinued November 16, 2022
Positive 1-Year and 2-Year OS Data for Patients with R/R AML in Ph 1 Actimab-A CLAG-M Combo Trial Announced November 16, 2022
Quizartinib Granted Priority Review in the U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML November 2, 2022
Gilead And MacroGenics Announce Oncology Collaboration To Develop Bispecific Antibodies October 26, 2022
MHRA and Research Ethics Committee Approvals Received to Initiate Ph 2B/3 AML Trials of OmnImmune March 24, 2022
